Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Developing Nations Home-Grow Genomics Research

By Drug Discovery Trends Editor | September 23, 2008

Developing countries that want the benefits of cutting-edge health care possibilities based on the genetic variation of individual citizens and sub-populations need to foster the new science at home, says a Canadian study.

In a supplement to Nature Reviews Genetics, researchers from the McLaughlin-Rotman Centre for Global Health (MRC), Toronto, say four countries with emerging economies—Mexico, India, Thailand, and South Africa—are showing the way for others in similar economic circumstances. The study details how those four countries are actively establishing domestic capacity in genomic medicine, efforts that will improve national health, slash medical costs through better resource allocation, and bolster their economies.

The two-year study was undertaken by Dr. Béatrice Séguin, Billie-Jo Hardy, Dr. Peter A. Singer and Prof. Abdallah S. Daar of the MRC, part of Toronto’s University Health Network and the University of Toronto.

“Benefits of this emerging science cannot be an exclusive luxury reserved for wealthier industrialized countries,” Séguin says. “Instead, it must be universally advanced by developed and developing countries alike to prevent an increased widening of already huge difference in global health care quality.”

The case studies revealed six major cross-cutting themes underlying initiatives in all four countries studied: political will, institutional leadership, the goal of producing local health benefits, protecting genomic sovereignty, and promoting economic benefits.

The authors describe what motivated the four countries to undertake these genomics initiatives, the mechanisms being used to develop genomic medicine appropriate to their circumstances, the potential for commercializing research results, and how challenges are being addressed, including ethical, legal, social and cultural issues that have either arisen or may arise.

Emerging economies and developing countries with investments in genomic initiatives will need to consider their next steps carefully. Among the paper’s proposals: ‘convergence centres’ for science, business and capital—an evolution beyond science parks and incubators—aimed at enhancing opportunities for knowledge sharing, rapid innovation, and a focus on product development and commercialization.

Release Date: September 18, 2008
Source: McLaughlin-Rotman Centre for Global Health  


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

DNA Script SYNTAX
DNA Script raises $165M Series C for DNA printing platform
DNA Script SYNTAX
DNA Script launches a benchtop DNA printer
DNA
Unraveling the promise of genetics for treating progressive illness 
Alzheimer's disease
How to build a foundation for the next phase of Alzheimer’s disease research

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50